SEC Form 4 · accession 0000919574-18-008127
Strongbridge Biopharma plc · SBBP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Dec 20, 2018
Accepted (ET)
Dec 21, 2018 · 6:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001634432
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares, $0.01 par valueF1,F2 | Dec 20, 2018 | P | 146,467 | $3.9967 | A | 6,441,296 | D | |
| Ordinary Shares, $0.01 par valueF3,F2 | Dec 21, 2018 | P | 90,612 | $3.9508 | A | 6,531,908 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.85 to $4.22 per share, inclusive. The Reporting Persons undertake to provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price.
- F2Following the transactions reported herein, these shares represent (a) 6,196,882 Ordinary Shares that are owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 335,026 Ordinary Shares beneficially owned by employees of an affiliate of Caxton Corporation and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation.
- F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.82 to $4.10 per share, inclusive. The Reporting Persons undertake to provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.